...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Cardoguard, an ayurvedic antihypertensive formulation, prevents cardiac remodeling in spontaneously hypertensive rats by inhibition of ERK and PKCσ signaling pathways
【24h】

Cardoguard, an ayurvedic antihypertensive formulation, prevents cardiac remodeling in spontaneously hypertensive rats by inhibition of ERK and PKCσ signaling pathways

机译:Cardoguard,一种阿育吠陀降压药,可通过抑制ERK和PKCσ信号通路来预防自发性高血压大鼠的心脏重塑

获取原文
获取原文并翻译 | 示例
           

摘要

Ayurveda is an Indian system of medicine. Despite clinical efficacy, lack of scientific validation has limited the effective use of Ayurvedic drugs. Cardoguard is an Ayurvedic antihypertensive drug formulated by Nagarjuna Herbal Concentrates Ltd., Kerala, India. Left ventricular hypertrophy (LVH) is a modifiable risk factor, and regression of LVH reduces the propensity for adverse cardiovascular events. This study was taken up with the objective of evaluating the efficacy of Cardoguard in the prevention of cardiac remodeling. Cardoguard was administered orally to 2-month-old spontaneously hypertensive rats for 4 months at a dose of 5 mg·day -1. The dose corresponds to the therapeutic dose calculated on the basis of body surface area. Lower hypertrophy index, decrease in cardiomyocyte area, and reduction of interstitial fibrosis in treated spontaneously hypertensive rats indicate amelioration of cardiac hypertrophy by Cardoguard. Cardiac output increased in response to treatment. Immunostaining for the phosphorylated components of major signaling pathways associated with hypertrophy suggests that prevention of LVH by Cardoguard is possibly mediated through inhibition of extracellular signal-regulated kinases and protein kinase C-3 signaling pathways. Reduced expression of 3-nitrotyrosine in response to the treatment suggests that prevention of cardiac remodeling by Cardoguard is mediated by reduction of oxidative stress.
机译:阿育吠陀是印度的医学体系。尽管具有临床疗效,但缺乏科学验证限制了印度草药药物的有效使用。 Cardoguard是由印度喀拉拉邦的Nagarjuna Herbal Concentrates Ltd.配制的一种印度草药降压药。左心室肥大(LVH)是一种可改变的危险因素,LVH的消退可降低发生不良心血管事件的可能性。进行这项研究的目的是评估Cardoguard预防心脏重构的功效。以5 mg·day -1的剂量对2个月大的自发性高血压大鼠口服Cardoguard 4个月。该剂量对应于基于体表面积计算的治疗剂量。在治疗的自发性高血压大鼠中,较低的肥大指数,心肌细胞面积的减少和间质纤维化的减少表明,Cardoguard可改善心肌肥大。治疗后心输出量增加。对与肥大相关的主要信号通路的磷酸化成分进行的免疫染色表明,Cardoguard预防LVH可能是通过抑制细胞外信号调节激酶和蛋白激酶C-3信号通路来介导的。响应治疗,3-硝基酪氨酸的表达降低表明Cardoguard预防心脏重塑是由氧化应激的降低介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号